Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30419444 | 0.85 | HSD11B1 (0.43) | OPRM1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL7157630 | 0.85 | HSD11B1 (0.43) | OPRM1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL16549656 | 0.84 | ADRA1A (0.55) | OPRM1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL1766193 | 0.84 | ADRA1A (0.44) | OPRM1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL6887265 | 0.84 | ADRA1A (0.52) | OPRM1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL626328 | 0.82 | GRIN1 (0.44) | OPRM1ADRA1AKMT2APRKCAPTPN2 | |
| SCHEMBL31221400 | 0.82 | GRIN1 (0.44) | OPRM1ADRA1AKMT2APRKCAPTPN2 | |
| SCHEMBL15862755 | 0.82 | GRIN1 (0.47) | OPRM1ADRA1AKMT2APRKCAPTPN2 | |
| SCHEMBL18711876 | 0.81 | ALDH1A1 (0.53) | ADRA1AKMT2APRKCAPTPN2HTR7 | |
| SCHEMBL8004598 | 0.81 | ADRA1A (0.53) | OPRM1ADRA1APRKCAPTPN2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| WO-2011084371-A1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| CN-101679406-A | Thiazolyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2010-03-24 | — | — | CN | disclosed |
| EP-2132203-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | OPRM1 85/4885ADRA1A 32/4885KMT2A 643/4885 |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, MTNR1B | OPRM1 5/4885ADRA1A 47/4885KMT2A 1189/4885 |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | OPRM1 76/4885ADRA1A 31/4885KMT2A 578/4885 |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | OPRM1 38/4885ADRA1A 53/4885KMT2A 692/4885 |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | TTBK1, ERBB2, TEC | OPRM1 4805/4885ADRA1A 3208/4885KMT2A 1431/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | OPRM1 85/4885ADRA1A 32/4885KMT2A 643/4885 |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | OPRM1 85/4885ADRA1A 32/4885KMT2A 643/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | OPRM1 38/4885ADRA1A 53/4885KMT2A 692/4885 |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | OPRM1 76/4885ADRA1A 31/4885KMT2A 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.